AstraZeneca’s Imfinzi trial shows ‘significantly improved’ event-free survival rates

by | Mar 9, 2023

Drugmaker AstraZeneca said on Thursday that results from a phase III trial on its resectable non-small cell lung cancer treatment had shown a “significantly improved” event-free survival.
AstraZeneca said results of the Imfinzi trial showed that treatment with the drug both before and after surgery “significantly increased” the time patients live without recurrence or progression events.

Results from the final pathologic complete response and major pathologic response analyses were consistent with previously announced positive results, and the trial will continue as planned to assess key secondary endpoints including disease-free survival and overall survival.

AstraZeneca’a Susan Galbraith said: “Patients with resectable non-small cell lung cancer face unacceptably high rates of recurrence, despite treatment with chemotherapy and surgery. We have shown that adding Imfinzi both before and after surgery significantly increased the time patients live without recurrence or progression events. We will continue to follow patients for overall survival.”

As of 0910 GMT, AstraZeneca shares were up 0.50% at 10,876.0p.

Reporting by Iain Gilbert at Sharecast.com

Related articles

Ryanair passenger numbers jump 9% in December

Ryanair passenger numbers jump 9% in December

(Sharecast News) - Budget airline Ryanair reported a 9% jump in December passenger numbers on Wednesday. Traffic rose to 12.54 million from 11.52m in the same month a year earlier, while the load factor - which gauges how full the planes are - ticked down to 91% from...

Wizz Are passenger numbers soar in December

Wizz Are passenger numbers soar in December

(Sharecast News) - Hungary-based budget airline Wizz Air reported a strong rise in December passenger numbers as demand continued to rebound from the Covid pandemic. The company on Wednesday said it carried 4,964,857 passengers, an 18.8% increase year on year. For the...

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!

x